The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial What we learn from subgroup analyses

被引：54
|
作者：
Ginsberg, Henry N. [1 ,2 ]
机构：
[1] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10027 USA
[2] Columbia Univ, Coll Phys & Surg, Irving Inst Clin & Translat Res, New York, NY USA
来源：
DIABETES CARE | 2011年 / 34卷
关键词：
CORONARY-HEART-DISEASE; LDL CHOLESTEROL; INTERVENTION; MEN; GEMFIBROZIL; PREVENTION; MORTALITY; THERAPY; PEOPLE;
D O I：
10.2337/dc11-s203
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S107 / S108
页数：2
相关论文
共 50 条
  • [21] Development of an Atrial Fibrillation Risk Score in Patients With Diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study
    Yang, Ping
    Zhao, Yanglu
    Wong, Nathan D.
    CIRCULATION, 2019, 140
  • [22] Diabetes Control Among Hispanics in the Action to Control Cardiovascular Risk in Diabetes Trial
    Asqual Getaneh
    Laney S. Light
    David J. Brillon
    Jorge Calles Escandón
    James Felicetta
    Gregory W. Evans
    Carlos R. Lopez-Jimenez
    Robert Cuddihy
    J. Thomas Bigger
    Journal of General Internal Medicine, 2012, 27 : 1499 - 1505
  • [23] Diabetes Control Among Hispanics in the Action to Control Cardiovascular Risk in Diabetes Trial
    Getaneh, Asqual
    Light, Laney S.
    Brillon, David J.
    Escandon, Jorge Calles
    Felicetta, James
    Evans, Gregory W.
    Lopez-Jimenez, Carlos R.
    Cuddihy, Robert
    Bigger, J. Thomas
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2012, 27 (11) : 1499 - 1505
  • [24] Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance
    Fleg, Jerome L.
    Evans, Gregory W.
    Margolis, Karen L.
    Barzilay, Joshua
    Basile, Jan N.
    Bigger, J. Thomas
    Cutler, Jeffrey A.
    Grimm, Richard
    Pedley, Carolyn
    Peterson, Kevin
    Pop-Busui, Rodica
    Sperl-Hillen, JoAnn
    Cushman, William C.
    HYPERTENSION, 2016, 68 (04) : 888 - 895
  • [25] Effects of Intensive Glucose Lowering in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
    Riddle, Matthew C.
    CIRCULATION, 2010, 122 (08) : 844 - 846
  • [26] The action to control cardiovascular risk in diabetes: Memory in diabetes (accord-mind) - Design and organization.
    Williamson, JD
    Miller, ME
    Bryan, N
    Lazaar, R
    Sullivan, M
    Launer, L
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S158 - S158
  • [27] Cost of Achieving A1C Treatment Goals in Patients with Type 2 Diabetes: Results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
    Zhang, Ping
    Shao, Hui
    Bertoni, Alain
    Lovato, Laura
    Chen, Haiying
    DIABETES, 2020, 69
  • [28] Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    Drake, T. C.
    Hsu, F. -C.
    Hire, D.
    Chen, S. -H.
    Cohen, R. M.
    McDuffie, R.
    Nylen, E.
    O'Connor, P.
    Rehman, S.
    Seaquist, E. R.
    DIABETES OBESITY & METABOLISM, 2016, 18 (01): : 92 - 95
  • [29] The action to control cardiovascular risk in diabetes memory in diabetes study (ACCORD-MIND): Rationale, design, and methods
    Williamson, Jeff D.
    Miller, Michael E.
    Bryan, R. Nick
    Lazar, Ronald M.
    Coker, Laura H.
    Johnson, Janice
    Cukierman, Tali
    Horowitz, Karen R.
    Murray, Anne
    Launer, Lenore J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12A): : 112I - 122I
  • [30] HbA1c trajectory and cardiovascular outcomes: an analysis of data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study
    Wang, Jun-Sing
    Liu, Wei-Ju
    Lee, Chia-Lin
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2021, 12
12345